StreetInsider.com News Articles

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Form 4 Vera Therapeutics, Inc. For: Jul 07 Filed by: Fordyce Marshall

Thu, 09 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260709/26753738.html

Form 4 Vera Therapeutics, Inc. For: Jul 07 Filed by: Fordyce Marshall

Thu, 09 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260709/26753738.html

Vera Therapeutics names Nancy Boman as chief regulatory officer

Thu, 09 Jul 2026 08:01:09 -0400

Vera Therapeutics, Inc. (Nasdaq: VERA) announced the appointment of Nancy Boman, M.D., Ph.D., as Chief Regulatory Officer, succeeding William Turner, who plans to retire and transition to a strategic advisor role in the third quarter of 2026.

Turner joined Vera Therapeutics and led the regulatory strategy that resulted in the accelerated approval of TRUTAKNA (atacicept-vymj), the company's therapy for IgA nephropathy (IgAN).

Boman brings more than 25 years of experience in regulatory affairs. She most recently served as Chief Regulatory Officer at Kyverna Therapeutics. Prior to that role, she held Chief Regulatory Officer positions at Adicet Bio, Encoded Therapeutics, and Novartis Gene

Vera Therapeutics names Nancy Boman as chief regulatory officer

Thu, 09 Jul 2026 08:01:09 -0400

Turner joined Vera Therapeutics and led the regulatory strategy that resulted in the accelerated approval of TRUTAKNA (atacicept-vymj), the company's therapy for IgA nephropathy (IgAN).

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Thu, 09 Jul 2026 08:00:00 -0400

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics’ first therapy in IgA nephropathy (IgAN), TRUTAKNA^™ (atacicept-vymj). Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory Officer of Vera Therapeutics.

“On behalf

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Thu, 09 Jul 2026 08:00:00 -0400

“On behalf

Form 8-K Vera Therapeutics, Inc. For: Jul 09

Thu, 09 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260709/26750414.html

Form 8-K Vera Therapeutics, Inc. For: Jul 09

Thu, 09 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260709/26750414.html

Vera Therapeutics (VERA) PT Raised to $78 at TD Cowen

Wed, 08 Jul 2026 08:09:35 -0400

TD Cowen analyst Ritu Baral raised the price target on Vera Therapeutics (NASDAQ: VERA) to $78.00 (from $73.00) while maintaining a Buy rating.

Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald on Trutakna Approval

Wed, 08 Jul 2026 07:47:23 -0400

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $100.00 price target on Vera Therapeutics (NASDAQ: VERA).

The analyst commented, "VERA announced that Trutakna (atacicept) received accelerated approval for IgA nephropathy (IgAN) based on its ability to reduce proteinuria, setting a launch in the coming weeks. The disclosed pricing for Trutakna is $425K/yr → this represents >$20B market opportunity in the US alone using conservative assumptions. The commercial infrastructure is fully built, positioning the company to execute the launch. We believe the Trutakna launch will be robust, mirroring OTSKY’s (NC) Voyxact, which has clear demand with 880 patient start forms

Vera Therapeutics (VERA) PT Raised to $76 at Guggenheim

Wed, 08 Jul 2026 06:50:22 -0400

(Updated - July 8, 2026 6:50 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Vera Therapeutics (NASDAQ: VERA) to $76.00 (from $56.00) while maintaining a Buy rating.

The analyst commented: "We are raising our Vera price target on the back of the company's transformative FDA approval of Trutakna (atacicept) Tuesday and our follow-up call with management last evening. We make a number of changes to our Vera company model and IgAN market model as a result, including increasing our probability of success to 100%, increasing our list price to the company's announced price of $425K/patient/year, and extending our base

Vera Therapeutics (VERA) PT Raised to $76 at Guggenheim

Wed, 08 Jul 2026 06:50:22 -0400

(Updated - July 8, 2026 6:50 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on Vera Therapeutics (NASDAQ: VERA) to $76.00 (from $56.00) while maintaining a Buy rating.

Vera Therapeutics (VERA) PT Raised to $125 at H.C. Wainwright

Wed, 08 Jul 2026 06:42:52 -0400

(Updated - July 8, 2026 6:42 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Vera Therapeutics (NASDAQ: VERA) to $125.00 (from $110.00) while maintaining a Buy rating.

The analyst commented: "As we expected, on July 7, the FDA granted accelerated approval (AA) to Trutakna (atacicept) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Trutakna became the first approved agent targeting both BAFF and APRIL for the treatment of IgAN. Consistent with our prior view, the indication carries no UPCR threshold, mirroring the broad language in the labels of Voyxact, marketed by

Vera Therapeutics (VERA) PT Raised to $125 at H.C. Wainwright

Wed, 08 Jul 2026 06:42:52 -0400

(Updated - July 8, 2026 6:42 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Vera Therapeutics (NASDAQ: VERA) to $125.00 (from $110.00) while maintaining a Buy rating.

Form 8-K Vera Therapeutics, Inc. For: Jul 07

Tue, 07 Jul 2026 12:46:00 -0400

si-local-file:///var/storage/secattach/20260707/26740897.html

Form 8-K Vera Therapeutics, Inc. For: Jul 07

Tue, 07 Jul 2026 12:46:00 -0400

si-local-file:///var/storage/secattach/20260707/26740897.html

FDA grants accelerated approval to Vera Therapeutics' kidney drug

Tue, 07 Jul 2026 12:39:51 -0400

Vera Therapeutics (Nasdaq: VERA) announced on July 7, 2026, that the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression.

The approval is based on a prespecified interim analysis of the ongoing ORIGIN 3 Phase 3 trial, in which participants treated with TRUTAKNA achieved a 46% reduction from baseline in proteinuria and a 42% reduction compared to placebo (p<0.0001) at 36 weeks. The interim analysis covered the first 203 participants who had received at least one dose of TRUTAKNA or placebo.

TRUTAKNA is a fusion